What Direct Meds does

Direct Meds is a private telehealth platform founded in 2024 and headquartered in Bluffdale, Utah, that connects patients with licensed healthcare providers for prescription-based weight loss and wellness treatments. Its core offering centers on compounded GLP-1 medications — semaglutide and tirzepatide, available in both injectable and sublingual formulations — prescribed through a self-serve digital funnel: a 60-second eligibility quiz, asynchronous provider review (with stated 6-hour turnaround), and direct-to-door shipping from licensed 503A compounding pharmacies within one business day. The platform is LegitScript-certified and HIPAA-compliant, and serves customers across 48 U.S. states (excluding Mississippi and Louisiana), with the company reporting more than 180,000 customers served as of April 2026.

Beyond GLP-1 weight management, the product portfolio has expanded into six adjacent verticals: anti-aging/longevity (NAD+, Sermorelin), hair loss (Minoxalune, Capilyn), pain relief (Ortharex), skin/aesthetic (Elastira), muscle recovery/energy, and supplements (Calocurb, Citradine, SatiaLean). All products are dispensed under provider supervision with bundled nursing support and all-inclusive subscription pricing — typically $224-$547 per month for GLP-1 SKUs and $59.99-$399.99 for ancillary wellness products, with HSA/FSA accepted.

The business operates on a direct-to-consumer cash-pay model with no insurance billing, targeting the estimated 24 million Americans who lost GLP-1 insurance coverage between 2025-2026. Distribution is entirely digital (directmeds.com and patient portal), with marketing concentrated in content/SEO, organic social, and earned media. The company completed an acquisition of Autumn DNA in June 2025, signaling intent to extend into genetic testing and personalized medicine.

Name

Direct Meds

Legal name

Direct Meds

Website

https://directmeds.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

101–250 employees

Short description

Direct Meds is a cash-pay telehealth platform connecting patients with licensed providers for compounded GLP-1 weight loss medications (semaglutide and tirzepatide) and adjacent wellness products, serving 180,000+ customers across 48 U.S. states on a monthly subscription model.

Ownership category

akta.pro rank

Product category

Direct-to-Consumer Telehealth

NAICS

Offices of Physicians (except Mental Health Specialists) (621111), Ambulatory Health Care Services (621), Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD)

Keywords

• Telehealth prescriptions
• Compounded GLP-1 medications
• Weight loss telehealth
• Direct-to-consumer pharmacy
• Online medical consultations

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Others

Revenue model

1. Subscription-based GLP-1 Programs: Monthly subscription model for GLP-1 weight loss programs including medication, physician consultation, nursing support, and shipping. All-inclusive pricing with no hidden fees or memberships.
2. Prescription Medications: Direct sale of compounded medications including semaglutide, tirzepatide, and other wellness products through the company's telehealth platform and patient portal.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Direct Meds is a direct-to-consumer telehealth company that connects patients with licensed medical providers for online consultations and prescriptions of compounded GLP-1 medications (semaglutide and tirzepatide) plus ancillary wellness products. After an online medical intake, a licensed provider reviews the patient and, if appropriate, issues a prescription that is fulfilled by partner compounding pharmacies and shipped directly to the patient's home.

Product overview

Direct Meds is a telehealth platform offering multiple health and wellness categories including Weight Loss/Body Composition, Anti-Aging/Longevity, Hair Loss/Hair Growth, Pain Relief & Recovery, Muscle Recovery/Energy/Performance, and Skin & Aesthetic. The core product portfolio centers on GLP-1-based medications (Semaglutide and Tirzepatide in both injectable and sublingual formulations) and extends to NAD+, peptide therapies (Sermorelin), natural supplements (Citradine/Sinetrol, SatiaLean/DNF-10, Calocurb), and topical treatments for hair loss (Minoxalune/Minoxidil, Capilyn/Finasteride), skin aging (Elastira), and pain management (Ortharex). All medications are delivered via direct-to-door shipping with integrated nursing support.

Differentiator

Problem solved

Functional benefit

Products and services

• Semaglutide Injection (Compounded GLP-1) Monthly compounded semaglutide injection for weight management, prescribed online by licensed providers after a telehealth intake and shipped to the patient.
• Semaglutide Sublingual Drops (Compounded) Daily compounded semaglutide drops administered under the tongue as an alternative to injectable GLP-1 for weight management, prescribed via telehealth and delivered monthly.
• Tirzepatide Injection (Compounded GLP-1/GIP) Monthly compounded tirzepatide injection for weight management, prescribed online after a telehealth consultation and shipped to the patient.
• Tirzepatide Sublingual Drops (Compounded) Daily compounded tirzepatide drops taken under the tongue as a needle-free alternative to injectable tirzepatide for weight management, prescribed via telehealth and delivered monthly.
• NAD+ Supplement NAD+ supplement offered as an ancillary wellness product available through the Direct Meds platform.
• Online Medical Consultation Online intake and provider review process that determines patient eligibility for treatment and issues the underlying prescription.

Quantifiable outcome

• Patients report reduced cravings and appetite control within 2-4 weeks; visible weight loss often begins by week 6
• +3 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Licensed 503A Compounding PharmaciescoreOthersPartnership with licensed 503A compounding pharmacies to prepare and dispense compounded GLP-1 medications (semaglutide and tirzepatide). These pharmacies prepare customized formulations under the supervision of licensed healthcare providers.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Henry Meds: Telehealth platform offering compounded GLP-1 weight loss programs with provider consultations and home delivery. Competes directly in the same cash-pay compounded GLP-1 segment as Direct Meds.
• LifeMD: Public telehealth company offering weight management programs including GLP-1 medications, plus primary care, men's health, and women's health. Directly comparable subscription-based DTC telehealth business model.
• Ro: Direct-to-consumer telehealth platform offering weight loss programs with GLP-1 medications along with men's health, women's health, and skincare. Operates a similar online qualification → consultation → pharmacy fulfillment model targeting cash-pay patients.
• Mochi Health: Telehealth platform focused on weight loss with compounded semaglutide and tirzepatide, offering provider consultations and ongoing support. Closely mirrors Direct Meds' core offering in the compounded GLP-1 niche.
• Found: Telehealth weight loss program combining prescription medications (including GLP-1s when appropriate) with coaching. Targets a similar cash-pay patient base with a subscription-based model.
• Hims & Hers Health: Public DTC telehealth platform offering weight loss programs including compounded GLP-1 medications, plus men's/women's wellness, hair loss, and skincare. Most direct and largest competitor to Direct Meds in the cash-pay GLP-1 telehealth category.

Broad incumbents

• PlushCare: Established telehealth provider (acquired by Accolade) offering online doctor consultations, prescriptions, and weight management programs. A broader incumbent in primary care telehealth with overlap in the GLP-1 space.
• Teladoc Health: Largest publicly-traded telehealth company offering broad virtual care including weight management and chronic condition management. A broad incumbent rather than niche GLP-1 specialist but operates in the same category.

Emerging players

• Sesame: DTC telehealth marketplace offering affordable online consultations and prescription medications including weight loss. Comparable cash-pay telehealth model targeting uninsured/underinsured patients.
• Strut Health: Telehealth platform offering compounded medications including hair loss, skincare, and weight loss treatments. Smaller but comparable product portfolio and DTC telehealth model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@DirectMeds
• Facebookfacebook.com/directmedsusa
• Instagraminstagram.com/direct_meds_usa

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Direct Meds